FREM2 and SPRY1 have been proposed as potential new markers of GBM, and have been demonstrated to be significantly upregulated in GBM at the mRNA and/or protein level in GBM cell lines and GBM tissues compared to references (astrocytes or reference non-malignant brain tissue) [6,19]. The gene discussed is SPRY1; the disease is glioblastoma.